Treatment of Children with Protein – Losing Enteropathy After Fontan and Other Complex Congenital Heart Disease Procedures in Condition with Limited Human and Technical Resources

Ramush Bejiqi, Ragip Retkoceri, Naim Zeka, Hana Bejiqi, Armend Vuqiterna, Arlinda Maloku

University of Prishtina, Prishtina, Kosova
Corresponding author: Ass. prof. Ramush Bejiqi, MD, PhD. University of Prishtina, Kosova. E-mail: rbejiqi@hotmail.com

ABSTRACT

Background Protein-losing enteropathy (PLE) is a disorder characterized by abnormal and often profound enteric protein loss. It’s relatively uncommon complication of Fontan and other complex congenital heart disease (CCHD) procedures. Because of the complexity and rarity of this disease process, the pathogenesis and pathophysiology of protein-losing enteropathy remain poorly understood, and attempts at treatment seldom yield long-term success. **Aim of presentation** is to describe single centre experience in diagnosis, evaluation, management and treatment of children with protein-losing enteropathy after Fontan and other CCHD procedures in the current era and in centre with limited human and technical resources, follows with a comprehensive review of protein-losing enteropathy publications, and concludes with suggestions for prevention and treatment.

Material and methodology Retrospectively we analyzed patients with CCHD and protein-losing enteropathy in our institution, starting from January 2000 to December 2012. The including criteria were age between two and 17 years, to have a complex congenital heart disease and available complete documentation of cardiac surgery under cardiopulmonary bypass. **Results** Of all patients we evaluated 18 cases with protein-losing enteropathy, aged 6 to 19 years (mean 14± 9); there were three children who had undergone screening procedure for D-transposition, one Tetralogy of Fallot, and remaining 14 patients had undergone Fontan procedures; (anatomic diagnosis are: six with tricuspid atresia, seven with d-transposition, double outlet right ventricle and pulmonary atresia and two with hypoplastic left heart syndrome). The diagnosis of protein-losing enteropathy was made at median age of 5.6 years, ranging from 13 months to 15 years. Diagnosis was made using alpha 1-antitrypsin as a gold marker in stool. By physical examination in 14 patients edema was found, in three ascites, and six patients had pleural effusion. Laboratory findings at the time of diagnosis are: abnormal enteric protein loss was documented at the time of diagnosis in all 18 patients. At the time of diagnosis all patients receiving some form of anticoagulation, 17 patients receiving other medication: 17 – diuretics and ACE inhibitors, 12 digoxin, 9 antiarrhythmics. Cross-sectional echocardiography was performed for all patients and different abnormalities were registered. In 14 patients also magnetic resonance was performed. Therapeutic approach was based on the non-specific medication (diet, diuretics, digoxin, ACE inhibitors, and anticoagulants), heparin and corticosteroids therapy. Long-term response to this type of therapy was registered in three patients. Nine patients underwent treatment with heparin and corticosteroids and no one experienced long term benefit. Despite of needs for catheter therapy or surgical intervention in our study, in the absent of technical and human resources now any one had underwent those procedures. Six patients has been transferred abroad and in five of them surgical intervention was perform.

Conclusion Protein-losing enteropathy remains a devastating complication of Fontan procedure and despite in advantages in surgical and medical therapy there is no evidence that protein-losing enteropathy is less common in the current area.

Key words tricuspid atresia, Fontan procedures, protein-losing enteropathy, complex congenital heart disease

1. BACKGROUND

The serum protein level reflects the balance between protein synthesis, metabolism, and protein loss. Protein-losing enteropathy is a disorder characterized by abnormal and often profound enteric protein loss from the digestive tract or the inability of the digestive tract to absorb proteins. (1) It is not a single disease, but an atypical manifestation of other diseases caused from bacterial or parasite infection, celiac sprue, Crohn’s disease, lymphoma, HIV infection or after surgical correction of the complex congenital heart disease (CCHD). Symptoms depend on the underlying disease that is causing the
protein-losing enteropathy. (2) Its relatively uncommon complication of Fontan and other CCHD procedures. Because of the complexity and rarity of this disease process, the pathogenesis and pathophysiology of protein-losing enteropathy remain poorly understood, and attempts at treatment seldom yield long-term success. As such, the signs and symptoms of protein-losing enteropathy are diverse and may be protean. For practical purposes, the disease processes that cause protein-losing enteropathy can be grouped into the following 3 major categories: a) lymphatic obstruction; b) mucosal erosion or ulceration, and c) epithelial cell dysfunction in the absence of macroscopic compromise. Although observations of protein losing enteropathy in the Fontan syndrome have been made for ten years and the presence of this condition in these patients carries a high mortality rate, its pathophysiology in this setting has still not been elucidated. Numerous publications have provided data to support various hypotheses including early elevations of postoperative central venous pressure, low pulmonary vascular compliance, and elevated serum hepatocyte growth factor. (3, 4)

**History** In 1949, Albright et al demonstrated an increase in protein turnover in patients with protein-losing enteropathy. In 1958, Citrin et al were the first to use radio labeled tracers to demonstrate the actual loss of a protein-containing fluid into the GI tract. Several additional diagnostic techniques using radio labeled substrates were developed, but a major advance was made when Crossley and Elliot demonstrated that measurement of alpha1-antitrypsin (A1-AT) levels in the stool was a reliable and simple test for protein-losing enteropathy. This approach has identified various conditions that have subclinical protein-losing enteropathy as a component of the disease process.

### 2. AIM OF PRESENTATION

The aim of presentation is to describe single centre experience in diagnosis, evaluation, management and treatment children with protein-losing enteropathy after Fontan and other CCHD procedures in the current era, follows with a comprehensive review of protein-losing enteropathy publications, and concludes with suggestions for prevention and treatment. In order to confirm the site of protein loss as originating from the intestinal tract, a test called “alpha-1-antitrypsin stool clearance” was performed. This involves the collection of stool over a 24 hour period of time and the drawing of a single blood specimen.

### 3. MATERIAL AND METHODOLOGY

Retrospectively we analyzed patients with CCHD and protein-losing enteropathy in our institution, starting from January 2000 to December 2012. The including criteria were age between two and 17 years, to have congenital heart disease and available complete documentation of cardiac surgery under cardiopulmonary bypass. Protein-losing enteropathy was defined as hypoalbuminemia and hypoproteinemia with no identifiable mode of protein loss other than the gastrointestinal tract. The diagnosis of protein losing enteropathy is typically made by excluding other causes of protein loss, such as nephrotic syndrome. Endoscopy and barium imaging can be used to localize the cause of the protein loss in the bowel. Faecal excretion of Alpha 1-antitrypsin was used as a marker of protein losing enteropathy.

### 4. RESULTS

Of all patients we evaluated 18 cases with protein-losing enteropathy, aged 6 to 19 years (mean 14± 9); there were three children who had undergone screening procedure for D-transposition, one Tetralogy of Fallot, and remaining 14 patients had undergone Fontan procedures; (anatomic diagnosis are: six with tricuspid atresia, seven with d-transposition, double outlet right ventricle and pulmonary atresia and two with hypoplastic left heart syndrome). The diagnosis of protein-losing enteropathy was made at median age of 5.6 years, ranging from 13 months to 15 years. Diagnosis was made using alpha 1-antitrypsin as a gold marker in stool. By physical examination in 14 patients edema was found, in three ascites, and six patients had pleural effusion. Laboratory findings at the time of diagnosis are: abnormal enteric protein loss was documented at the time of diagnosis in 18 patients. At the time of diagnosis all patients receiving some form of anticoagulation, 17 patients receiving other medication: 17 – diuretics and ACE inhibitors, 12 digoxin, 9 antiarrhythmics. Cross-sectional echocardiography was performed for all patients and different abnormalities were registered. In 14 patients also magnetic resonance was performed. Therapeutic approaches for protein-losing enteropathy depend on the underlying etiology. In our study therapeutic approach was based on the non-specific medication (diet, diuretics, digoxin, ACE inhibitors, and anticoagulants) and specific treatment: heparin and corticosteroids therapy. Non-specific medical therapy, using diuretic therapy, digoxin and angiotensin-converting enzyme aimed to decrease central venous pressure and improve cardiac function. Long-term response to this type of therapy was registered in three patients. Despite needs for catheter therapy or surgical intervention in our study, in the absent of technical and human resources now any one had underwent those procedures. Six patients has been transferred abroad and in five of them surgical intervention was perform. One patient died during the surgery, where previously surgical correction of tetralgy has been done.

**Signs and symptoms** A complete dietary history should be obtained to evaluate for possible protein malnutrition, which results in diminished albumin synthesis. Despite strictly defined protein –losing enteropathy being the excessive loss of serum proteins into the gastrointestinal lumen, the simplicity of this definition belies the complexity of the disease process, the manifestations of which are not limited to hypoalbuminemia and secondary clinical phenomena, including hematologic and immunologic abnormalities. (5,6) Non-specific symptoms of dyspnoea or fatigue are common. Some degree of peripheral oedema, ascites, pleural or pericardial effusions are less common. Gastrointestinal findings such as diarrhoea, steatorrhoea or melena are relatively uncommon. Uncontrolled protein-losing enteropathy may present...
Protein-losing enteropathy (PLE) is a protein normally found in the blood and stool. If PLE is present, the quantity in the stool increases in relation to the blood sample, indicating that protein loss is originating from the gut. Alpha-1-Antitrypsin or \( \alpha_1 \)-antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin. It is a protein normally found in the blood and in the stool. If PLE is present, the quantity in the stool increases in relation to the blood sample, indicating that protein loss is originating from the gut. Alpha-1-Antitrypsin or \( \alpha_1 \)-antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin.

The diagnosis of PLE is made on the basis of history and data for surgical correction of CCHD, clinical symptoms and laboratory confirmation. Alpha-1-antitrypsin is a protein normally found in the blood and in the stool. If PLE is present, the quantity in the stool increases in relation to the blood sample, indicating that protein loss is originating from the gut. Alpha-1-Antitrypsin or \( \alpha_1 \)-antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum antitrypsin.

Protein-losing enteropathy is a poorly understood and enigmatic disease process affecting patients with single ventricle after Fontan operation. In those afflicted, PLE after Fontan operation results in significant morbidity and mortality. The pathophysiology of the disease is unknown; however, a proposed mechanism incorporates a combination of phenomena including: a) altered hemodynamics, specifically low cardiac output; b) increased mesenteric vascular resistance; c) systemic inflammation; and d) altered enterocyte basal membrane glycosaminoglycan make-up.

A paradigm for the clinical management of PLE after Fontan operation is proposed. In the early 1970’s, Dr. Francois Fontan developed and formalized an intriguing concept where he felt that if conditions were appropriate, venous blood returning from the body could be channeled to the lungs in a passive fashion without the use of a ventricular pumping chamber. By effectively connecting the veins carrying blood returning from the body (vena cavae) directly to the vessels carrying blood to the lungs (pulmonary arteries), blood circulatory patterns similar to that found in the normal heart could be achieved. The use of a staged surgical approach resulting in the Fontan operation has allowed for the survival of many children with a variety of complex defects, including tricuspid atresia, single left ventricle, and hypoplastic left heart syndrome (HLHS). Protein-losing enteropathy occurs in up to 10% of patients following the modified Fontan procedure and it is a serious complication of a Fontan operation with a very high mortality rate. Further investigation is needed to determine the exact mechanism of the disease and to develop new therapeutic approaches. As the number of survivors after the Fontan operation has increased, protein-losing enteropathy has been noted to occur in some children within a few weeks after the Fontan operation, or years later, in children who are otherwise doing well from a cardiovascular standpoint.

Heparin is thought to possibly have a stabilizing effect on the capillary endothelium, reducing protein leakage into the extra vascular space and gut lumen, although the precise mechanism of action is unknown. Although heparin has been successfully used to treat some patients with protein-losing enteropathy that develops after the Fontan procedure, it is by no means the treatment of choice for all the etiologies of protein-losing enteropathy. (7) Nine patients underwent treatment with heparin and corticosteroids and no one experienced long term benefit. Despite of needs for catheter therapy or surgical intervention in our study, in the absent of technical and human resources now any one had underwent those procedures. Six patients has been transferred abroad and in five of them surgical intervention was perform.

Corticosteroids including budesonide, have been used in patients with protein-losing enteropathy associated with collagen vascular diseases, inflammatory bowel disease, or after Fontan procedure to complex congenital heart disease. In our cohort group 14 children have been treated with Methyl-prednisolon, (2mg/kg) and in 12 children level of Alpha-1-antitrypsin at stool has decreased. Treatment with oral prednisone attenuated the protein loss with subsequent normalization of her serum total protein and albumin levels. Discontinuation of prednisone therapy was associated with relapse, which was again treated successfully with low-dose oral prednisone.

Sporadic case reports have documented the successful use of other agents such as cyclosporine for protein-losing enteropathy. Immunosuppressive drugs should not be used in cases of protein-losing enteropathy secondary to infections. In our study we didn’t use any type of immunosuppressive therapy.

Diet

In patients whose protein-losing enteropathy is related to lymphatic pathology, decreasing the lymphatic circulation provides some benefit. This requires dietary limitation of long-chain triglycerides because their absorption from the gut stimulates lymphatic flow. In order to provide adequate energy, medium-chain triglycerides must be added as an alternative source of lipid calories. As described below, fat soluble vitamins must also be supplemented because their absorption is compromised in these patients. (4) All patients from our cohort have undergone dietary limitation of long-chain triglycerides with fat soluble vitamins supplements. Long-term response to this type of therapy was registered in 11 patients.

Treatment with oral prednisone attenuated the protein loss with subsequent normalization of her serum total protein and albumin levels. Discontinuation of prednisone therapy was associated with relapse, which was again treated successfully with low-dose oral prednisone.

6. CONCLUSION

Protein-losing enteropathy remains a devastating complication of Fontan procedure and despite in advantages in surgical and medical therapy there is no evidence that protein-losing enteropathy is less common in the current area. Despite the pathogenesis and pathophysiology of protein-losing enteropathy remaining poorly understood, there is small evidence to implicate lymphatic in-
sufficiency as central to the disease process. All patients diagnosed with or at risk for protein-losing enteropathy require regular evaluation for adequate growth and evidence of fat-soluble vitamin (ADEK) deficiencies.

**Recommendation** all patients diagnosed with or at risk for protein-losing enteropathy requires regular evaluation for adequate growth and evidence of fat-soluble vitamin (ADEK) deficiencies. Patients who develop protein-losing enteropathy after Fontan procedures represent a particularly vulnerable cohort with a high rate of significant morbidity and mortality. Close follow-up coupled with an aggressive approach to reverse this problem is warranted.

Familiarize the patient and his or parents with the signs of edema and the earliest signs and symptoms of fat-soluble vitamin deficiency, and inform them that increased infections could be secondary to loss of immunoglobulins and/or lymphocytes. An ongoing relationship with the physician and frequent monitoring is essential to minimize morbidity (9).

**CONFLICT OF INTEREST: NONE DECLARED**

**REFERENCES**

1. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment; Cardiology in the Young. 2011; 21: 363-377.

2. Greenwald DA. Protein losing enteropathy. In: Feldman M, Friedman L.S, Brandt LJ eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010.

3. Meadows J, Gauvreau K, Jenkins K. Lymphatic obstruction and protein-losing enteropathy following Fontan procedure. Am J Cardiol. 2001; 88:1206-1209.

4. Holmgren D, Berggren H, Wahländer H, Hallberg M, Myrdal U. Reversal of protein-losing enteropathy in a child with Fontan circulation is correlated with central venous pressure after heart transplantation. Pediatr Transplant. 2001 Apr; 5(2): 135-137.

5. Mertens L, Hagler DJ, Sauer U, Sommerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study, PLE study group. J Thorac Cardiovasc Surg. 1998 May; 115(5): 1063-1073.

6. Therrien J, Webb GD, Gatzoulis MA. Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? Heart. 1999 Aug; 82(2): 241-243.

7. Liu M, Liu L, Zhou HM. Reversal of protein-losing enteropathy with heparin therapy in a patient after Fontan operation. Zhonghua Er Ke Za Zhi. 2009 Jan; 47(1): 76-77.

8. Bode L, Munch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem. 2006 Mar 24; 281(12): 7809-7815.

9. Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr. 1997 Mar; 130(3): 47.

**INSTRUCTIONS FOR THE AUTHORS**

All papers need to be sent to: Editorial board of the journal Mat Soc Med, electronically over the web site http://scopemed.org/?jid=16. Every article sent to Mat Soc Med gets its number, and author(s) will be notified if their paper is accepted and what is the number of the paper. Original paper could not contain more than 5,000 words. Review articles more than 4,500 and Case report more than 1,500 words, including references. Every correspondence will use that number. The paper has to be typed on a standard format (A4), leaving left margins to be at least 3 cm. All materials, including tables and references, have to be typed double-spaced, so that one page has no more than 2000 alphanumeric characters (90 lines) and total number of used words must not be more than 3,500. Preventing paper depends on its content, but usually it consists of a title page, summary, text references, legends for pictures and picture. Type your paper in MS Word and send it on a diskette or a CD-ROM, so that the editing of your paper will be easier.

Every article has to have a title page with a title of no more than 10 words: name(s), last and first of the author(s), name of the institution the author(s) belongs to, abstract with maximum of 45 letters (including space), footnote(s) with acknowledgments, name of the first author or another person with whom correspondence will be maintained.

The paper needs to contain structured summary, 200 words at the most. Summary needs to hold title, full name(s) and surname(s) of the author(s) and coauthor(s), work institution, and all essential facts of the work, introduction, formulation of purposes, problem of work, used methods, (with specific data, if possible) and basic facts. Summary must contain the re-view of underlined data, ideas and conclusions from text. Summary must have no quoted references. Four key words, at the most, need to be placed below the text.

Authentic papers contain these parts: introduction, goal, methods, results, discussion and conclusion. Introduction is brief and clear review of the problem. Methods are shown, so that interested reader is able to repeat described research. Known methods don’t need to be identified, they are cited (referenced). If drugs are listed, their generic name is used, (brand name can be written in brackets). Results need to be shown clearly and logically, and their significance must be proven by statistical analysis. In discussion, results are interpreted and compared to the existing and previously published findings in the same field. Conclusions have to give an answer to author’s goals.

Quoting references must be on a scale, in which they are usually quoted. Using most recent literature is recommended. Only published articles, (or articles accepted for publishing), can be used as references. Not published observations and personal notifications need to be in text in brackets. Shown references must be as how they appear in the text. References cited in tables or pictures are also numbered according to the quoting order. All references should be compiled at the end of the article in the Vancouver style or published style (i.e., www.scopemed.org).

Tests used for statistical analysis need to be shown in text and in tables or pictures containing statistical analysis. Tables have to be numbered and shown by their order, so they can be understood without having to read the paper. Every column needs to have a title, every measuring unit (SI) has to be clearly marked (i.e. prefer- ably in footnotes below the table, in Arabic numbers or symbols). Pictures also have to be numbered as they appear in the text. Drawings need to be enclosed on a white or tracing paper, white and black photos have to be printed on a radiant paper. Legends (e.g. notes to pictures and photos), have to be written on a separate A4 formal paper. All illustrations, pictures, drawings, diagrams, have to be original, and on their backs contain, illustration number, first author’s last name, abbreviated title of the paper and picture at the top. It is appreciated, if author marks the place for the table or picture. Papers could not be submitted with included more of 4 Tables, Figures or Graphs. Every additional must be paid 20 euros each.

Use of abbreviations have to be reduced to a minimum. Conventional units can be used without their defini- tion. Supplement, if paper contains original contribution to a statistical method or author believes, without quoting original computer program, that paper’s value will be reduced. Editorial staff will consider possibility of publishing mathematics /statistical analysis in extension.

Any practice of plagiarism will not be tolerated regarding submitted articles. Non-identifiable quoted parts of the articles from other authors are known act of plagiarism if it is not cited or referencing in appropriate places in the article. Advertent practice of plagiarism self about reviewing process or article submission. Author(s) may suggest or exclude peer-re-viewers for their articles but Editorial Board has the right to reject their(s) opinions or suggestions according to copyright Assignment form signed by authors before reviewing process. Authors must respect guidelines and rules of ICMJE, WAME, COPE, ICMJE guidelines available at www.icmje.org. All authors listed as authors should qualify for authorship and should have participated sufficiently in the work to take public responsibility for appropriate portions of the content and follow the next conditions: a) substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data; b) drafting the article or revising it critically for important intellectual content; c) final approval of the version to be published (all co-authors must sign copyright Assignment form downloaded from www.avicenapublisher.org). All other contributors to the article’s subject who does not qualify for authorship should be listed in acknowledgement section. For all relevant information about authorship follow ICMJE guidelines. All authors must make a formal statement at the time of submission indicating any potential conflict of in- terest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflict of interest might include, but not limited to, share holding in or receipt of grant or consultancy free form a company whose product features in the submitted-manuscript or which manufactures a competing product. All authors must submit a statement of conflict of interest to be published at the end of their article (conflict of Interest: non declared).

**ORIGINAL PAPER • Mater Sociomed. 2014 Feb; 26(1): 39-42**